Literature DB >> 7430628

Inherited deficiency of the ninth component of complement in man.

T F Lint, H J Zeitz, H Gewurz.   

Abstract

A 76-year-old man was found to have low (33% normal) serum complement (C) hemolytic activity, although C3 and C4 protein levels were normal. Further evaluation of his serum and plasma indicated that all C components were present in normal or elevated amounts except for C9, which was undetectable by both antigenic and functional assays. Addition of purified human C9 led to full restoration of the hemolytic activity. Family studies demonstrated that the deficiency was inherited as an autosomal codominant trait and was not linked with alleles at the HLA-A or HLA-B loci. The patient had no history of recurrent or unusual infections and no evidence of autoimmune disease. The availability of serum totally lacking in C9 permitted an investigation of the lytic capacity of the C5b-8 segment of the C attack mechanism, which was pursued in kinetic studies on the hemolysis of erythrocyte intermediates. These studies indicated that hemolysis occurred approximately 100 times slower in patient than in normal serum, using either EA or EAC1-7 intermediates as target cells. Serum bactericidal activity also was slower in patient serum, occurring at a rate about 1/35 that observed in normal serum. These studies provide direct independent evidence that cytolysis of erythrocytes and bacteria can be mediated by C5b-8, and allow a quantitative estimation of the increment in the rates of these reactions provided by normal serum levels of C9. The presence of readily detectable though slow hemolytic activity of C9-deficient serum may account for the difficulty in identifying individuals with this defect.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7430628

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Complement induces a transient increase in membrane permeability in unlysed erythrocytes.

Authors:  J A Halperin; A Nicholson-Weller; C Brugnara; D C Tosteson
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

2.  Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Authors:  Erika M Cook; Margaret A Lindorfer; Hilma van der Horst; Simone Oostindie; Frank J Beurskens; Janine Schuurman; Clive S Zent; Richard Burack; Paul W H I Parren; Ronald P Taylor
Journal:  J Immunol       Date:  2016-07-29       Impact factor: 5.422

3.  Are complement lysis and lymphocytotoxicity analogous?

Authors:  P J Lachmann
Journal:  Nature       Date:  1983 Oct 6-12       Impact factor: 49.962

Review 4.  Bactericidal and bacteriolytic activity of serum against gram-negative bacteria.

Authors:  P W Taylor
Journal:  Microbiol Rev       Date:  1983-03

5.  C9 deficiency in a patient with poststreptococcal glomerulonephritis.

Authors:  K Maruyama; H Arai; T Ogawa; M Hoshino; S Tomizawa; A Morikawa
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

Review 6.  Infections of people with complement deficiencies and patients who have undergone splenectomy.

Authors:  Sanjay Ram; Lisa A Lewis; Peter A Rice
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9.

Authors:  K A Joiner; M A Schmetz; M E Sanders; T G Murray; C H Hammer; R Dourmashkin; M M Frank
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

8.  SLE-like and sicca symptoms in late component (C9) complement deficiency.

Authors:  M Sugimoto; M Nishikai; A Sato; Y Suzuki; M Nihei; J Uchida; N Mimura
Journal:  Ann Rheum Dis       Date:  1987-02       Impact factor: 19.103

9.  Mechanism of killing of Giardia lamblia trophozoites by complement.

Authors:  M Deguchi; F D Gillin; I Gigli
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.